Orchard Therapeutics (NASDAQ: ORTX) stock - it’s the ADS - is up 94% this morning. There’s a buyout for the company on the table. Obviously we’ve missed the jump in ORTX stock but it’s still true that there’s a little bit of value to be had - the contingents are, currently, for free.
Orchard recently had the FDA accept a priority action: “Orchard Therapeutics (NASDAQ:ORTX) stock jumped 13% in afternoon trading Monday after the company said that its Biologics License Application for its drug OTL-200 had been accepted by the FDA under its priority review program, with a decision expected by March 18.” That boosted the share price on its own. But not all that much for it is indeed just the acceptance of an application, not the approval of it.
It’s what came next that is behind this latest jump: “Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, and Orchard Therapeutics plc (Orchard Therapeutics, Nasdaq: ORTX), a global gene therapy leader, today announced the companies have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics for $16.00 per American Depositary Share (ADS) in cash (approximately $387.4 million, or ¥57.3 billion), under which Orchard shareholders will hold an additional contingent value right (CVR) of $1.00 per ADS. An additional $1.00 CVR will be paid for a total of $17.00 per ADS, or approximately $477.6 million (¥70.7 billion) if the conditions are met.”
OK, so $16 cash now.

Orchard Therapeutics stock price from Nasdaq
The basic idea here is not unusual. The larger pharma companies allow the small to do all the development work and then, if that pans out, they swoop in to be able to sell the new cure through their distribution networks.
It’s also not unusual to have those contingent rights. But what’s interesting here is that even now, after the announcement, it’s possible to get those contigents for free. Well, for the interest cost of holding Orchard Thera until completion. The stock is below the cash price, meaning buying now and holding would leave a cash flat position but also possession of that contingent. True, that’s not a very exciting trade but it is one that at current prices is a lock in.
The value of the trade depends rather on what we think those contingents are worth - “up to $1 - is a pretty wide range.



